Invitrogen Corporation Develops New Technology to Promote Safer Stem Cell Therapies
Published: May 04, 2009
CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced a new technology to enable the development of safer stem cell therapies. Dynabeads® SSEA-4, addresses a key challenge in translational research by separating undifferentiated stem cells from those that are differentiated. Scientists from Invitrogen and the Buck Institute for Age Research, located in Novato, Calif., collaborated in developing this innovative solution that depletes greater than 99% of undifferentiated human embryonic stem cells from differentiated populations. They are presenting data on this new technology at the International Society for Cellular Therapy Meeting in San Diego.